JNJ 📈 Johnson & Johnson - Overview

Exchange: NYSE • Opening Hours • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4781601046

JNJ: Medicines, Medical Devices, Contact Lenses, Intraocular Lenses

Johnson & Johnson is a global healthcare leader that researches, develops, manufactures, and sells a wide range of products to improve human health and well-being. Through its Innovative Medicine segment, the company offers a diverse portfolio of prescription medications that cater to various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

These medications are designed to treat a broad spectrum of conditions, such as rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis, HIV/AIDS, mood disorders, neurodegenerative disorders, schizophrenia, prostate cancer, hematologic malignancies, lung cancer, bladder cancer, thrombosis, diabetes, and macular degeneration. The company distributes these products to healthcare professionals, hospitals, wholesalers, and retailers, ensuring that they reach patients who need them most.

The MedTech segment of Johnson & Johnson is focused on developing innovative medical devices and technologies that improve patient outcomes. This segment offers a range of Interventional Solutions, including electrophysiology products to treat heart rhythm disorders, as well as technologies to treat severe coronary artery disease and cardiogenic shock. Additionally, the company provides neurovascular care solutions for hemorrhagic and ischemic stroke, and an orthopaedics portfolio that supports hips, knees, trauma, spine, sports, and other procedures.

Furthermore, the MedTech segment offers advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures. The company is also a leading provider of contact lenses under the ACUVUE Brand, and TECNIS intraocular lenses for cataract surgery. Johnson & Johnson distributes its MedTech products to hospitals, physicians, nurses, eye care professionals, and clinics, ensuring that they are accessible to those who need them.

With a rich history dating back to 1886, Johnson & Johnson is headquartered in New Brunswick, New Jersey, and has established itself as a trusted and reliable partner in the healthcare industry. The company's commitment to innovation, quality, and customer satisfaction has earned it a reputation as a global leader in the healthcare sector.

Additional Sources for JNJ Stock

JNJ Stock Overview

Market Cap in USD 368,366m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1944-09-24

JNJ Stock Ratings

Growth 5y 37.8
Fundamental 72.7
Dividend 57.2
Rel. Performance vs Sector -0.69
Analysts 3.78/5
Fair Price Momentum 142.33 USD
Fair Price DCF 209.49 USD

JNJ Dividends

Dividend Yield 12m 2.40%
Yield on Cost 5y 3.05%
Dividends CAGR 5y 4.62%
Payout Consistency 96.03%

JNJ Growth Ratios

Growth Correlation 3m -76.8%
Growth Correlation 12m 39.4%
Growth Correlation 5y 58.1%
CAGR 5y 4.93%
CAGR/Mean DD 5y 0.71
Sharpe Ratio 12m 0.03
Alpha vs SP500 12m -13.57
Beta vs SP500 5y weekly 0.48
Volatility GJR Garch 1y 16.62%
Current Volume 9061.3k
Average Volume 20d 7172.4k
What is the price of JNJ stocks?
As of November 21, 2024, the stock is trading at USD 153.11 with a total of 9,061,274 shares traded.
Over the past week, the price has changed by -0.08%, over one month by -5.97%, over three months by -3.68% and over the past year by +4.53%.
Is Johnson & Johnson a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Johnson & Johnson (NYSE:JNJ) is currently (November 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 72.69 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JNJ as of November 2024 is 142.33. This means that JNJ is currently overvalued and has a potential downside of -7.04%.
Is JNJ a buy, sell or hold?
  • Strong Buy: 8
  • Buy: 2
  • Hold: 13
  • Sell: 0
  • Strong Sell: 0
Johnson & Johnson has received a consensus analysts rating of 3.78. Therefor, it is recommend to hold JNJ.
What are the forecast for JNJ stock price target?
According to ValueRays Forecast Model, JNJ Johnson & Johnson will be worth about 155.1 in November 2025. The stock is currently trading at 153.11. This means that the stock has a potential upside of +1.28%.
Issuer Forecast Upside
Wallstreet Target Price 174.9 14.2%
Analysts Target Price 168.5 10%
ValueRay Target Price 155.1 1.3%